Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 121

Sort by

Sort Order Select

Journal Articles

Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial

Blood blood.2025029210.

https://doi.org/10.1182/blood.2025029210

Published: 2025

Includes: Supplemental data

Journal Articles

A machine learning approach identifies a transcriptomic signature predicting treatment-free remission in chronic myeloid leukemia

Vincent Alcazer, Stéphanie Dulucq, Isabelle Mosnier, Kaddour Chabane, Pauline Bertin-Mourot, Sandrine Derruau, Marie Balsat, Hélène Labussière-Wallet, Pierre Sujobert, François-Xavier Mahon, Gabriel Etienne, Franck Nicolini, Sandrine Hayette

Blood (2025) 146 (Supplement 1): 76.

https://doi.org/10.1182/blood-2025-76

Published: 2025

Journal Articles

Distinct patterns of mutant ASXL1 over time and their implications for treatment failure (TF) and BCR::ABL1 mutation development in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS-TKI) in the ASC4FIRST study

Blood (2025) 146 (Supplement 1): 73.

https://doi.org/10.1182/blood-2025-73

Published: 2025

Journal Articles

High rates of deep molecular response (DMR) in patients (pts) with chronic myeloid leukemia in chronic Phase (CML-CP) who have not achieved dmr after ≥1 year of prior imatinib (IMA) in the asciminib (ASC) monotherapy arm of the Phase 2 ASC4MORE study

Jorge Cortes, Giuseppe Saglio, Jan Geissler, Jiri Mayer, Gabriel Etienne, Michael Fillitz, Elvira Mora Casterá, Shruti Kapoor, Ana Paula Cardoso, Ugo Okoroji, Amila Sarac, Matthias Hoch, Sara Quenet, Timothy Hughes

Blood (2025) 146 (Supplement 1): 5552.

https://doi.org/10.1182/blood-2025-5552

Published: 2025

Journal Articles

Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial

Blood (2025) 146 (Supplement 1): 5549.

https://doi.org/10.1182/blood-2025-5549

Published: 2025

Journal Articles

Additional genetic abnormalities (AGA) and microhomology end-joining DNA repair (MMEJ) signatures influence the outcome of newly diagnosed chronic phase (CP) CML: Ancillary study of the Trial of imatinib after ponatinib induction (TIPI)

Franck Nicolini, Francoise Huguet, Aude Charbonnier, Martine Escoffre-Barbe, Gabrielle Roth-Guepin, Shanti Amé, Emilie Cayssials, Mathieu Meunier, Charlotte Doublet, Vincent Alcazer, Stéphane Morisset, Romaine Mayet, Gwenaëlle Garin, Gabriel Etienne, Ivan Sloma, Olivier Mansier, Stéphanie Dulucq

Blood (2025) 146 (Supplement 1): 3773.

https://doi.org/10.1182/blood-2025-3773

Published: 2025

Journal Articles

Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis

Blood (2025) 146 (Supplement 1): 1997.

https://doi.org/10.1182/blood-2025-1997

Published: 2025

Journal Articles

ASC4OPT 96-week results: Asciminib once or twice daily continues to be highly efficacious and demonstrates favorable safety in patients with chronic myeloid leukemia and suboptimal response, resistance or intolerance to two or more tyrosine kinase inhibitors

Blood (2025) 146 (Supplement 1): 1993.

https://doi.org/10.1182/blood-2025-1993

Published: 2025

Journal Articles

Increased Thromboinflammation Is Associated with High Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Multicentric Study of 394 Cases By the French Intergroup of Myeloproliferative Neoplasms (FIM)

Blood (2024) 144 (Supplement 1): 3133.

https://doi.org/10.1182/blood-2024-194702

Published: 2024

Journal Articles

Bosutinib for Patients with Previously Treated Chronic Myeloid Leukemia: Results from the French Observational Boseval Study

Philippe Rousselot, Jean-Christophe Ianotto, Philippe Quittet, Maya Hacini, Gabrielle Roth-Guepin, Mathieu Meunier, Frederic Maloisel, Valérie Coiteux, Gabriel Etienne

Blood (2024) 144 (Supplement 1): 3150.

https://doi.org/10.1182/blood-2024-200145

Published: 2024

Journal Articles

18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting

Blood (2024) 144 (Supplement 1): 478.

https://doi.org/10.1182/blood-2024-198903

Published: 2024

Journal Articles

Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study

Jorge E. Cortes, Andreas Hochhaus, Timothy P Hughes, Jianxiang Wang, Dong-Wook Kim, Dennis Dong Hwan Kim, Jiri Mayer, Yeow Tee Goh, Philipp le Coutre, Gabriel Etienne, Naoto Takahashi, Inho Kim, David Andorsky, Ghayas C. Issa, Felice Bombaci, Shruti Kapoor, Rajendra Jinwal, Lillian Yau, Richard Larson

Blood (2024) 144 (Supplement 1): 475.

https://doi.org/10.1182/blood-2024-203757

Published: 2024

Journal Articles

Asciminib Shows High Efficacy and Favorable Tolerability at 80 Mg Once Daily and 40 Mg Twice Daily in Patients with Chronic Phase Chronic Myelogenous Leukemia Previously Treated with 2 or More Tyrosine Kinase Inhibitors: Primary Analysis from the ASC4OPT Study

Blood (2024) 144 (Supplement 1): 4526.

https://doi.org/10.1182/blood-2024-200017

Published: 2024

Journal Articles

Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study

Blood (2023) 142 (Supplement 1): 1800.

https://doi.org/10.1182/blood-2023-173132

Published: 2023

Journal Articles

Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure: A Report from the Residiag Study

Hippolyte Guerineau, Jean-Michel Cayuela, Stéphanie Dulucq, Violaine Tran Quang, Sihem Tarfi, Quentin Barathon, Corine Joy, Orianne Wagner-Ballon, Stéphane Morisset, Franck E. Nicolini, Lydia Roy, Sébastien Maury, Gabriel Etienne, Delphine Rea, Ivan Sloma

Blood (2023) 142 (Supplement 1): 4540.

https://doi.org/10.1182/blood-2023-186271

Published: 2023

Journal Articles

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Blood (2023) 142 (Supplement 1): 445.

https://doi.org/10.1182/blood-2023-181571

Published: 2023

Journal Articles

Treatment Patterns, Tolerance, and Clinical Response of Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients (Including Those Harboring the T315I Mutation) Experiencing Multiple Tyrosine Kinase Inhibitor Failure: A Multi-Center Retrospective Chart Review Analysis

Franck E. Nicolini, Francoise Huguet, Lynn Huynh, Churong Xu, Christophe Bouvier, Aurore Yocolly, Gabriel Etienne

Blood (2022) 140 (Supplement 1): 9656–9658.

https://doi.org/10.1182/blood-2022-160268

Published: 2022

Journal Articles

Prospective Follow-up of Patients with Myelofibrosis (MF) and Treated with Ruxolitinib in France: The Rumycup Study

Jean-Jacques Kiladjian, Françoise Boyer perrard, Kamel Laribi, Jean-Christophe Ianotto, Dana Ranta, Omar Benbrahim, Serge Bologna, Pascale Cony-Makhoul, Alberto Santagostino, Hacene Zerazhi, Abla Slimani, Olivier Fitoussi, Gabriel Etienne

Blood (2022) 140 (Supplement 1): 3968–3969.

https://doi.org/10.1182/blood-2022-156628

Published: 2022

Journal Articles

Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience

Blood (2022) 140 (Supplement 1): 12335–12338.

https://doi.org/10.1182/blood-2022-163478

Published: 2022

Journal Articles

Last Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase” in Patients with TKI-Resistant or Intolerant CML

Emilie Cayssials, Gabriel Etienne, Ali G Turhan, Philippe Rousselot, Valerie Coiteux, Marc G. Berger, Francoise Huguet, Agnes Guerci-Bresler

Blood (2022) 140 (Supplement 1): 6776–6777.

https://doi.org/10.1182/blood-2022-166111

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial

A machine learning approach identifies a transcriptomic signature predicting treatment-free remission in chronic myeloid leukemia

High rates of deep molecular response (DMR) in patients (pts) with chronic myeloid leukemia in chronic Phase (CML-CP) who have not achieved dmr after ≥1 year of prior imatinib (IMA) in the asciminib (ASC) monotherapy arm of the Phase 2 ASC4MORE study

Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial

Additional genetic abnormalities (AGA) and microhomology end-joining DNA repair (MMEJ) signatures influence the outcome of newly diagnosed chronic phase (CP) CML: Ancillary study of the Trial of imatinib after ponatinib induction (TIPI)

Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis

ASC4OPT 96-week results: Asciminib once or twice daily continues to be highly efficacious and demonstrates favorable safety in patients with chronic myeloid leukemia and suboptimal response, resistance or intolerance to two or more tyrosine kinase inhibitors

Increased Thromboinflammation Is Associated with High Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Multicentric Study of 394 Cases By the French Intergroup of Myeloproliferative Neoplasms (FIM)

Bosutinib for Patients with Previously Treated Chronic Myeloid Leukemia: Results from the French Observational Boseval Study

18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting

Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study

Asciminib Shows High Efficacy and Favorable Tolerability at 80 Mg Once Daily and 40 Mg Twice Daily in Patients with Chronic Phase Chronic Myelogenous Leukemia Previously Treated with 2 or More Tyrosine Kinase Inhibitors: Primary Analysis from the ASC4OPT Study

Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study

Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure: A Report from the Residiag Study

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Treatment Patterns, Tolerance, and Clinical Response of Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients (Including Those Harboring the T315I Mutation) Experiencing Multiple Tyrosine Kinase Inhibitor Failure: A Multi-Center Retrospective Chart Review Analysis

Prospective Follow-up of Patients with Myelofibrosis (MF) and Treated with Ruxolitinib in France: The Rumycup Study

Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience

Last Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase” in Patients with TKI-Resistant or Intolerant CML

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only